Latest Period
Q4 2025
Security Snapshot
Traws Pharma, Inc. - Common stock, par value $.01 per share (TRAW) Institutional Ownership
CUSIP: 68232V884
13F Institutional Holders and Ownership History from Q3 2024 to Q1 2026
Institutions Reporting
21
Shares (Excl. Options)
3,418,588
Price
$1.13
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common stock, par value $.01 per share
- Symbol
- TRAW on Nasdaq
- Shares outstanding
- 8,133,373
- Price per share
- $1.83
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 3,418,588
- Total reported value
- $3,863,003
- % of total 13F portfolios
- 0%
- Share change
- +1,351,193
- Value change
- +$1,409,923
- Number of holders
- 21
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- TRAW - Traws Pharma, Inc. - Common stock, par value $.01 per share is tracked under CUSIP 68232V884.
- 21 institutions reported positions in Q4 2025.
- 8 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 21 to 2 between Q4 2025 and Q1 2026.
- Reported value moved from $3,863,003 to $27,827.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 21 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 68232V884?
CUSIP 68232V884 identifies TRAW - Traws Pharma, Inc. - Common stock, par value $.01 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 68232V884:
Significant Owners of Traws Pharma, Inc. - Common stock, par value $.01 per share (TRAW) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 10% | 0% | $1,641,628 | +$632,468 | 886,887 | +63% | Perceptive Advisors LLC | 30 Sep 2025 |
| Ikarian Capital, LLC | 10% | 0% | $1,308,164 | +$359,065 | 812,524 | +38% | Ikarian Capital, LLC | 31 Dec 2025 |
| ORBIMED ADVISORS LLC | 20% | $1,164,061 | 760,824 | ORBIMED ADVISORS LLC | 31 Dec 2024 | |||
| Adage Capital Management, L.P. | 9.1% | +89% | $1,175,300 | +$644,000 | 730,000 | +121% | Adage Capital Management, L.P. | 31 Dec 2025 |
| Squadron Capital Management LLC | 8.9% | +6.2% | $1,148,799 | +$197,289 | 713,540 | +21% | Squadron Master Fund LP | 31 Dec 2025 |
| Chernett Jorey | 6.8% | $668,220 | 543,268 | Chernett Jorey | 14 Jan 2026 | |||
| Ayrton Capital LLC | 4.3% | -56% | $552,125 | -$97,751 | 342,935 | -15% | Ayrton Capital LLC | 31 Dec 2025 |
| Alyeska Investment Group, L.P. | 9.9% | $462,446 | 302,252 | Alyeska Investment Group, L.P. | 31 Dec 2024 |
As of 31 Dec 2025, 21 institutional investors reported holding 3,418,588 shares of Traws Pharma, Inc. - Common stock, par value $.01 per share (TRAW). This represents 42% of the company’s total 8,133,373 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Traws Pharma, Inc. - Common stock, par value $.01 per share (TRAW) together control 42% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 9% | 730,000 | +121% | 0% | $824,900 |
| Squadron Capital Management LLC | 8.8% | 713,540 | 0% | 0.36% | $806,300 |
| Ikarian Capital, LLC | 8.3% | 678,142 | +2280% | 0.1% | $766,299 |
| ORBIMED ADVISORS LLC | 7.4% | 605,531 | 0% | 0.01% | $684,250 |
| BOOTHBAY FUND MANAGEMENT, LLC | 2.4% | 194,536 | 0.01% | $219,826 | |
| ADAR1 Capital Management, LLC | 1.9% | 154,431 | 0.01% | $174,507 | |
| VANGUARD GROUP INC | 1.1% | 87,259 | 0% | 0% | $98,603 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.76% | 61,653 | +42% | 0% | $69,668 |
| Seven Fleet Capital Management LP | 0.61% | 49,260 | 0% | 0.04% | $55,664 |
| XTX Topco Ltd | 0.52% | 42,210 | +294% | 0% | $47,697 |
| STATE STREET CORP | 0.32% | 25,802 | 0% | $29,156 | |
| CITADEL ADVISORS LLC | 0.31% | 24,819 | 0% | $28,045 | |
| TWO SIGMA INVESTMENTS, LP | 0.24% | 19,244 | -13% | 0% | $21,746 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.17% | 14,197 | 0% | $16,043 | |
| BlackRock, Inc. | 0.12% | 9,956 | 0% | 0% | $11,250 |
| UBS Group AG | 0.09% | 7,722 | +128600% | 0% | $8,726 |
| SBI Securities Co., Ltd. | 0% | 162 | 0% | 0% | $183 |
| BANK OF AMERICA CORP /DE/ | 0% | 113 | +11% | 0% | $128 |
| OSAIC HOLDINGS, INC. | 0% | 8 | 0% | $9 | |
| FMR LLC | 0% | 2 | 0% | 0% | $2 |
| CITIGROUP INC | 0% | 1 | -100% | 0% | $1 |
| ASSETMARK, INC | 0% | 0 | -100% | $0 | |
| HRT FINANCIAL LP | 0% | 0 | -100% | $0 | |
| MORGAN STANLEY | 0% | 0 | -100% | $0 | |
| Vestal Point Capital, LP | 0% | 0 | -100% | $0 |
Institutional Holders of Traws Pharma, Inc. - Common stock, par value $.01 per share (TRAW) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 15,206 | $27,827 | +$27,531 | $1.83 | 2 |
| 2025 Q4 | 3,418,588 | $3,863,003 | +$1,409,923 | $1.13 | 21 |
| 2025 Q3 | 1,304,595 | $2,413,244 | +$101,966 | $1.85 | 18 |
| 2025 Q2 | 1,263,487 | $1,869,962 | -$1,075,287 | $1.48 | 19 |
| 2025 Q1 | 1,732,309 | $3,984,315 | +$1,207,345 | $2.30 | 18 |
| 2024 Q4 | 1,141,975 | $10,140,752 | +$4,400,867 | $8.88 | 17 |
| 2024 Q3 | 646,356 | $3,800,574 | +$3,742,033 | $5.88 | 10 |